Results 201 to 210 of about 222,802 (316)

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen   +14 more
wiley   +1 more source

Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature. [PDF]

open access: yesCancers (Basel)
Sotoca Rubio P   +12 more
europepmc   +1 more source

Applying machine learning to pharmacovigilance data: A proof‐of‐concept study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Machine learning (ML) applications in pharmacovigilance remain limited and underexplored. Using data from the French National pharmacovigilance database (FNPV), this proof‐of‐concept study aimed to assess the feasibility of using a ML algorithm—eXtreme Gradient Boosting (XGBoost)—combined with SHapley Additive exPlanations (SHAP) analysis, to ...
Romain Barus   +6 more
wiley   +1 more source

Magnetoelastic Cell Monitoring System for Evaluating the Effects of Surface Chemistry on the Performance of Mesenchymal Stem Cell Growth

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT The recent clinical adoption of cell therapies has increased the need for more efficient, robust, and reproducible manufacturing technologies. Human mesenchymal stromal cells (hMSCs), a major component of the cell and immunotherapeutic market, remain challenging to manufacture at scale because they require surface attachment and are highly ...
William S. Skinner   +7 more
wiley   +1 more source

Macrophage‐targeted cerium‐tannic acid metal‐polyphenol framework nanoenzyme promotes in situ heart valves regeneration through adaptive immunomodulation

open access: yesBMEMat, EarlyView.
A novel nanoenzyme based on cerium ions‐tannic acid metal‐polyphenol framework (FCT) has been developed and loaded onto DHVs for targeting M1 macrophages to reduce their ROS level and reprogram macrophage phenotype, thereby eliminating inflammation, promoting endothelialization and adaptive matrix remodeling of scaffolds, offering a promising strategy ...
Peng Song   +9 more
wiley   +1 more source

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

open access: yesBMEMat, EarlyView.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy